SAR405: Selective ATP-Competitive Vps34 Inhibitor for Precise Autophagy Inhibition

Executive Summary: SAR405, available from APExBIO, is a potent ATP-competitive inhibitor of Vps34, a class III phosphoinositide 3-kinase, with a Kd of 1.5 nM and IC50 of 1 nM for human recombinant enzyme, showing high selectivity against class I/II PI3Ks and mTOR up to 10 μM (APExBIO SAR405). SAR405 blocks autophagosome formation by disrupting Vps34 kinase activity, leading to late endosome-lysosome dysfunction and preventing cathepsin D maturation (Park et al., 2023). Its inhibitory action synergizes with mTOR inhibitors and is validated in GFP-LCLC3 HeLa and H1299 cell lines. SAR405's unique selectivity enables precise dissection of Vps34-dependent pathways in cancer and neurodegenerative disease models (SAR405: Advancing Autophagy and Vesicle Trafficking). Storage and solubility parameters are well-defined, supporting robust experimental reproducibility.

Biological Rationale

Autophagy is a conserved catabolic process essential for cellular homeostasis, especially under nutrient or energy stress (Park et al., 2023). Vps34, the only class III PI3K in mammals, is central to autophagosome nucleation and vesicle trafficking. Dysregulation of autophagy and vesicle trafficking is implicated in cancer, neurodegeneration, and lysosomal storage disorders (Precision Modulation of Autophagy). By inhibiting Vps34, SAR405 provides a targeted approach to dissect mechanisms underlying autophagy-dependent cellular processes—distinct from broad-spectrum PI3K or mTOR inhibitors.

Mechanism of Action of SAR405

SAR405 is an ATP-competitive inhibitor that binds selectively within the ATP-binding cleft of Vps34, blocking its lipid kinase activity. It exhibits a dissociation constant (Kd) of 1.5 nM and inhibits Vps34 with an IC50 of 1 nM in biochemical assays (APExBIO). SAR405 does not inhibit class I or II PI3Ks, nor mTOR, at concentrations up to 10 μM. By inactivating Vps34, SAR405 impedes autophagosome formation and blocks downstream autophagic flux. This results in impaired late endosome-lysosome fusion, swelling of late endosomal-lysosomal compartments, and defective maturation of cathepsin D. The blockade of Vps34-dependent PI(3)P production is central to its mode of action (Park et al., 2023).

Evidence & Benchmarks

• SAR405 inhibits human recombinant Vps34 with an IC50 of 1 nM and Kd of 1.5 nM, demonstrating high potency (APExBIO, product page).
• SAR405 does not inhibit class I/II PI3Ks or mTOR at concentrations up to 10 μM, confirming remarkable selectivity (APExBIO).
• In GFP-LCLC3 HeLa and H1299 cells, SAR405 prevents autophagosome formation and autophagy, phenocopying Vps34 knockdown (Park et al., 2023).
• SAR405 causes accumulation of swollen late endosome-lysosome compartments and blocks cathepsin D maturation in vitro (Park et al., 2023).
• SAR405 synergizes with mTOR inhibitors (e.g., everolimus) to suppress autophagy more completely than either agent alone (SAR405 and the Vps34 Kinase Pathway).
• SAR405 is soluble in DMSO above 10 mM but insoluble in water; it is soluble in ethanol upon ultrasonic treatment (APExBIO, product page).

Compared to Precision Modulation of Autophagy, this article details quantitative potency and selectivity benchmarks for SAR405, directly updating and extending earlier qualitative reviews.

Applications, Limits & Misconceptions

SAR405 is widely deployed as a research tool to dissect the Vps34 kinase signaling pathway in cancer and neurodegenerative disease models. Its selectivity enables the study of autophagy inhibition without confounding effects from class I/II PI3K or mTOR pathways (SAR405: Advancing Autophagy). Key applications include:

• Dissecting autophagosome formation and PI(3)P-dependent trafficking.
• Modeling lysosome dysfunction and vesicle trafficking impairment.
• Synergy testing with mTOR inhibitors in cancer cell lines.
• Investigating autophagy's role during metabolic and energy stress states.

By contrast, SAR405: Precision Vps34 Inhibition focuses on strategic deployment; this article provides updated mechanistic caveats and quantitative solubility guidance.

Common Pitfalls or Misconceptions

• SAR405 is not effective in inhibiting class I or II PI3K isoforms or mTOR even at 10 μM; it is not a pan-PI3K inhibitor (APExBIO).
• SAR405-induced autophagy inhibition can be cell-type and context dependent; metabolic state and AMPK activation may alter outcomes (Park et al., 2023).
• Long-term storage of SAR405 solutions is not recommended; frequent freeze-thaw cycles may degrade compound potency (APExBIO, product page).
• SAR405 is not soluble in aqueous buffers; inappropriate solvent use will result in precipitation and unreliable dosing.
• SAR405 does not block autophagy induced independently of Vps34 (e.g., non-canonical pathways).

Workflow Integration & Parameters

SAR405 (SKU A8883) is provided as a powder by APExBIO, recommended to be dissolved in DMSO (>10 mM) or ethanol (with ultrasonic assistance). For in vitro assays, stock solutions should be prepared fresh and stored below -20°C. Working concentrations commonly range from 10–1000 nM, depending on cell type and endpoint. Avoid repeated freeze-thaw cycles. SAR405 can be combined with mTOR inhibitors for mechanistic synergy studies. Readout endpoints include LC3 puncta quantification, cathepsin D maturation assays, and late endosome-lysosome morphology. For detailed protocol adaptations, see the SAR405 product page and SAR405: Advancing Autophagy (which focuses on practical troubleshooting, while this article emphasizes mechanism and selectivity).

Conclusion & Outlook

SAR405 represents a gold-standard tool for selective ATP-competitive Vps34 inhibition, enabling precise autophagy inhibition and vesicle trafficking modulation in biomedical research. Its unique selectivity profile, validated potency, and well-characterized solubility parameters distinguish it from other PI3K or autophagy inhibitors. As models of AMPK-ULK1-Vps34 signaling evolve, SAR405 provides clarity in dissecting canonical versus non-canonical autophagy pathways (Park et al., 2023). Future research will benefit from its integration into combinatorial and context-specific studies across cell types and disease models.